Last edition
News about "Kashiv BioSciences "
Kashiv BioSciences and CRISTALIA Partner to Bring Omalizumab Biosimilar to Latin America
Kashiv BioSciences, LLC (Kashiv), a US-based vertically integrated biopharmaceutical company, has entered into a licensing and supply agreement with CRISTÁLIA, one of Brazil’s leading pharmaceutical companies, to commercialize ADL-018 / bOmalizumab, a proposed biosimilar to Xolair, in Latin America (LATAM).
Kashiv BioSciences | 14/09/2025 | By Darshana
Kashiv Biosciences, MS Pharma Partner to Commercialise Xolair Biosimilar in MENA Region
Kashiv BioSciences and MS Pharma have entered into an exclusive licensing and supply agreement for the commercialization of ADL-018, Kashiv’s biosimilar candidate to XOLAIR (bOmalizumab) in the Middle East and North Africa (MENA) region.
Kashiv BioSciences | 07/08/2025 | By Dineshwori | 131
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy